Contribution of Rs780094 and Rs1260326 Polymorphisms in GCKR Gene to Nonalcoholic Fatty Liver Disease: A Meta-Analysis Involving 26,552 Participants

Author(s):  
Jiaying Li ◽  
Yuening Zhao ◽  
Hongxiang Zhang ◽  
Wenxi Hua ◽  
Wenzhi Jiao ◽  
...  

Background:: Many published studies attempted to elucidate the implication of glucokinase regulator gene (GCKR) polymorphisms in the susceptibility to nonalcoholic fatty liver disease (NAFLD), but the results among them were still with controversy. Objective:: This meta-analysis aims to precisely assess the relationship between the GCKR polymorphisms and the risk of NAFLD. Methods:: Systematic computerized searches in six databases were performed and updated to April 6, 2020. Meta-analyses were conducted by calling the R programs based on accumulated epidemiological data. Odds ratio (OR) and 95% confidential interval (CI) were calculated to summarize the effect estimates. Results:: In total, 25 studies involving 6,598 cases and 19,954 controls were included. The pooled estimates indicated that the T allele carrier of the GCKR rs780094 polymorphism has predisposition to NAFLD (allele model: OR: 1.20, 95% CI: 1.11~1.29; homozygote model: OR: 1.38, 95% CI: 1.15~1.67; heterozygote model: OR: 1.25, 95% CI: 1.12~1.39; dominant model: OR: 1.29, 95% CI: 1.13~1.47; recessive model: OR: 1.18, 95% CI: 1.06~1.31), and the same as the rs1260326 polymorphism (allele model: OR: 1.32, 95% CI: 1.22~1.42; homozygote model: OR: 1.65, 95% CI: 1.40~1.94; heterozygote model: OR: 1.24, 95% CI: 1.07~1.43; dominant model: OR: 1.39, 95% CI: 1.21~1.59; recessive model: OR: 1.44, 95% CI: 1.28~1.62). Further stratified analyses according to age and ethnicity confirmed the statistical existence in most subgroups. Conclusion:: This meta-analysis suggested that both of the GCKR rs780094 and rs1260326 polymorphisms are significantly associated with the increased risk of NAFLD.

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Xiaoyun Wei ◽  
Chunyan Wang ◽  
Shijun Hao ◽  
Haiyan Song ◽  
Lili Yang

Aim. To assess the efficacy of berberine in the treatment of nonalcoholic fatty liver disease through meta-analysis.Method. We searched Embase, Pubmed, Cochrane Library, and so forth, until March 2016 for randomized controlled trials using berberine to treat NAFLD.Result. Six randomized controlled trials involving 501 patients were included in this study. The results showed that the efficacy of reducing TC, LDL, ALT, 2hPG, and HbA1c in NAFLD patients of the berberine group were significantly higher than that of control group. The subgroup analyses on TG, AST, and FBG indicated that treatment combined with berberine decreased TG level in NAFLD patients significantly. Compared with other drugs, berberine alone decreased TG level in NAFLD patients significantly. We also conducted a descriptive analysis on insulin resistance and radiography results that berberine can improve NAFLD patients’ insulin resistance and fatty liver.Conclusion. According to analysis result, berberine has positive efficacy on blood lipids, blood glucose, liver function, insulin resistance, and fatty liver condition of NAFLD patients. However, due to the limitation of number and quality of trials included, more clinical randomized controlled trials with high quality are needed for further verification of the efficacy of berberine on NAFLD patients.


2019 ◽  
Vol 38 (6) ◽  
pp. 2552-2557 ◽  
Author(s):  
Yong-Ping Chen ◽  
Feng-Bin Lu ◽  
Yi-Bing Hu ◽  
Lan-Man Xu ◽  
Ming-Hua Zheng ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document